Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK starts build of its largest Indian tablet manufacturing pharmaceutical factory in Vemgal, Karnataka
Hon’ble Chief Minister of Karnataka, Shri Siddaramaiah lays the foundation stone of the new pharmaceutical factory
Read more -
GSK and Theravance announce results from the SUMMIT COPD CV Survival Study
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced initial results from the Study to Understand Mortality and MorbidITy in COPD (SUMMIT) for...
Read more -
New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression
ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study
Read more -
Regulatory update: GSK and Theravance announce intention to file Relvar® Ellipta® for COPD in Japan
GlaxoSmithKline (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the intention to file a supplemental Japanese New Drug Application (sJNDA) for Relvar® Ellipt...
Read more -
GSK receives positive CHMP opinion in Europe for novel anti-IL5 biological Nucala (mepolizumab) for the treatment of patients with severe refractory eosinophilic asthma
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opini...
Read more -
GSK presents post-hoc analysis of Anoro® Ellipta® data assessing markers of COPD deterioration compared to tiotropium or placebo using a novel composite endpoint
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced data presented by GSK at the European Respiratory Society (ERS) International Congress (poster PA1001)
Read more -
GSK submits regulatory application for chlorhexidine gel for the prevention of umbilical cord infections in newborn babies
GSK today announced that it has submitted a regulatory application to the European Medicines Agency (EMA) for its antiseptic chlorhexidine gel (7.1% chlorhexidine digluconate ge...
Read more -
GSK announces positive new data comparing Incruse® Ellipta® to tiotropium and glycopyrronium in patients with COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive results from two head-to-head studies directly comparing the efficacy and safety of Incruse® Ellipta® (umeclidinium)...
Read more -
GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension
GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension
Read more -
GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study)
GSK today announced that, as per the stepwise trial design of its losmapimod phase III study, LATITUDE-TIMI 60, an interim review of data from part A of the study (an initial co...
Read more -
GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the second pivotal phase III study of its candidate vaccine Shingrix™ in adults aged 70 years and over (known as ZOE-70)...
Read more -
GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of patients with asthma
GlaxoSmithKline plc (GSK) today announced results from the ‘LABA’ (long acting beta2-agonist) safety study, AUSTRI (SAS115359).
Read more -
Results announcement for the third quarter 2015
Q3 sees continued progress in execution of Group strategy Sales of £6.1 billion (+11% CER) and core EPS of 23.0p (-13% CER)
Read more -
GSK profiles innovative R&D portfolio to investors
40 potential new medicines and vaccines offer significant opportunity to drive long-term performance and deliver new benefits to patients and consumers
Read more -
ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Phase IIb study LATTE 2 (NCT02120352) met i...
Read more -
GSK and Merck to study immunotherapy combination as potential cancer treatment
Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda® (pembrolizumab)
Read more -
GSK’s Nucala® (mepolizumab) receives approval from US FDA
First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype
Read more -
GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) administered subcutaneously in patients with systemic lupus erythematosus
GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) administered subcutaneously in patients with systemic lupus erythematosus
Read more -
GSK receives European marketing authorisation to expand indication for Volibris® in treatment of pulmonary arterial hypertension
GSK today announced that the European Commission has approved a variation to expand the current therapeutic indication for Volibris® (ambrisentan) to include its use in combinat...
Read more -
GSK announces start of phase III study of sirukumab in Giant Cell Arteritis
GSK today announced that dosing has commenced in a phase III study evaluating sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the treatment of patients with ...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
